IRX5010 / Io Therap - LARVOL DELTA

Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor (GlobeNewswire) - "The presentation...was delivered as a late-breaking abstract at the San Antonio Breast Cancer Symposium 2024....The presented studies showed treatment of the EMT-6 mouse model of triple negative breast cancer with IRX5010 plus a checkpoint inhibitor monoclonal anti-PDL-1 resulted in substantial 84% inhibition of tumor growth. This was a 9% increase of inhibitory effect on tumor growth of the combination over treatment with anti-PDL-1 alone....Additive or synergistic effects on each of these outcomes were observed with the combination treatment of IRX5010 with anti-PDL-1."

Preclinical • Triple Negative Breast Cancer

The RAR gamma nuclear receptor agonist IRX5010 has combination inhibitory effects with an anti-PDL-1 checkpoint inhibitor on the growth of EMT-6 triple negative breast cancer (SABCS 2024) - "Treatment of the EMT-6 murine model of triple negative breast cancer with the RAR gamma selective agonist compound IRX5010 plus the checkpoint inhibitor monoclonal murine anti-PDL-1 resulted in 84% inhibition of tumor growth, a 9% increase of inhibitory treatment effect over anti-PDL-1 alone. Combination treatment with IRX5010 with monoclonal anti-PD-1 had only modest additive effects on inhibition of EMT-6 tumor growth. All treatment regimens were well tolerated as assessed by change in weight."

Checkpoint inhibition • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • RARG

RAR gamma agonist compounds inhibit tumor growth, promote effector memory tumor infiltrating T-cells, and inhibit tumor infiltrating myeloid derived suppressor cells in multiple cancer models (SITC 2024) - "We performed in vivo evaluation of three RARg agonist compounds: IRX4647, IRX5010, and tazarotenic acid, in syngeneic murine models of NSCLC (Lewis Lung Cancer), triple negative breast (EMT6), colorectal (MC38), and prostate cancer (MyC-CaP). These data support that RARg agonism is a potential new approach for immunotherapy of cancers. They expand studies recently published by our collaborators at the Frederick National Laboratory for Cancer Research with ourselves, which demonstrated effects of our first generation RARg agonist IRX4647 on tumor growth and immune microenvironment in a murine model of NSCLC, with increased TILs, and combination treatment effects on lung tumor growth with anti-PD-L1 checkpoint inhibitor.2"

IO biomarker • Myeloid-derived suppressor cells • Preclinical • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • B2M • CD8 • HER-2 • RARG

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers (GlobeNewswire) - "The presented studies showed that oral treatment with IRX5010 resulted in suppression of growth in mouse models of each of four studied types of the most prevalent and deadly cancers in humans, i.e. triple negative breast, Her-2 positive breast, colorectal, and prostate cancers. In all four models, treatment with IRX5010 induced increased numbers of tumor infiltrating total and effector memory phenotype T-lymphocytes (TIL) associated with reduction in tumor growth. In the colorectal and prostate cancer models, IRX5010 also suppressed numbers of tumor infiltrating myeloid derived suppressor cells (MDSC)."

Preclinical • Colorectal Cancer • HER2 Positive Breast Cancer • Prostate Cancer • Triple Negative Breast Cancer

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound (GlobeNewswire) - "Io Therapeutics, Inc., presented today results from studies done in breast, lung, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010....The presentation...was delivered at the Federation of American Societies for Experimental Biology (FASEB) Seventh International Conference on Retinoids....The presented studies showed that oral treatment with IRX5010 resulted in suppression of growth in mouse models of each of five types of the most prevalent and deadly cancers in humans, i.e. triple negative breast, Her-2 positive breast, non-small cell lung, colorectal, and prostate cancers. In all five models, treatment with IRX5010 induced tumor infiltrating effector memory phenotype T-lymphocytes associated with reduction in tumor growth. Treatment with IRX5010 did not directly impact growth of cancers cells in tissue cultures, indicating that the compound is not significantly directly toxic to cancer cells."

Preclinical • Colorectal Cancer • HER2 Positive Breast Cancer • Non Small Cell Lung Cancer • Prostate Cancer • Triple Negative Breast Cancer